Please assess the completion status of the following clinical trial:

Trial Title: An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer between 60-90 days old;~* Healthy volunteers who fulfill all the required conditions for receiving the investigational vaccine as established by medical history and clinical examination and determined by investigators;~* Proven legal identity;~* Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;~* Complying with the requirement of the study protocol;~Exclusion Criteria:~* Prior vaccination with Poliovirus Vaccine;~* History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;~* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;~* Autoimmune disease or immunodeficiency/immunosuppressive;~* Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;~* Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) prior to study entry;~* Blood product prior to study entry;~* Any other investigational medicine(s) within 30 days prior to study entry;~* Any live attenuated vaccine within 14 days prior to study entry;~* Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;~* Acute disease or acute stage of chronic disease within 7 days prior to study entry;~* Axillary temperature \> 37.0 °C;~* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.~Intervention: investigational sIPV
- Control Group (Type: ACTIVE_COMPARATOR): The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV

Based on this trial design, predict the completion outcome and termination type (if applicable).